ERBB2 and breast carcinoma: In the case of hormone-positive HER2-positive breast cancer cell lines, the increased ER signaling and its transcriptional activity in response to lapatinib were described as a source of lapatinib resistance enhancing FOXO3a and caveolin-1 expression (212).